Oral anticoagulation in device-detected atrial fibrillation: effects of age, sex, cardiovascular comorbidities, and kidney function on outcomes in the NOAH-AFNET 6 trial

Gregory Y H Lip, Julius Nikorowitsch, Susanne Sehner, Nina Becher, Emanuele Bertaglia, Carina Blomstrom-Lundqvist, Axel Brandes, Vincent Beuger, Melanie Calvert, A John Camm, Gregory Chlouverakis, Gheorghe-Andrei Dan, Wolfgang Dichtl, Hans Christoph Diener, Alexander Fierenz, Andreas Goette, Joris R de Groot, Astrid Hermans, Andrzej Lubinski, Eloi MarijonBéla Merkely, Lluís Mont, Ann-Kathrin Ozga, Kim Rajappan, Andrea Sarkozy, Daniel Scherr, Renate B Schnabel, Ulrich Schotten, Emmanuel Simantirakis, Tobias Toennis, Panos Vardas, Dan Wichterle, Antonia Zapf, Paulus Kirchhof*, NOAH‐AFNET 6 investigators

*Corresponding author for this work

Research output: Contribution to journalJournal articleResearchpeer-review

11 Downloads (Pure)
Original languageEnglish
JournalEuropean Heart Journal
Volume45
Issue number19
Pages (from-to)1733-1737
ISSN0195-668X
DOIs
Publication statusPublished - 14. May 2024

Keywords

  • Anticoagulation
  • Atrial fibrillation
  • Atrial high-rate episodes
  • Bleeding
  • CHA2DS2-VASc score
  • Device-detected atrial fibrillation
  • Kidney function
  • NOAH-AFNET 6
  • Stroke
  • Age Factors
  • Administration, Oral
  • Cardiovascular Diseases/prevention & control
  • Comorbidity
  • Humans
  • Male
  • Treatment Outcome
  • Anticoagulants/administration & dosage
  • Stroke/prevention & control
  • Sex Factors
  • Atrial Fibrillation/drug therapy
  • Female
  • Aged

Cite this